Logo image of MIRM

MIRUM PHARMACEUTICALS INC (MIRM) Stock Fundamental Analysis

USA - NASDAQ:MIRM - US6047491013 - Common Stock

72.17 USD
-0.54 (-0.74%)
Last: 10/13/2025, 8:00:00 PM
72.17 USD
0 (0%)
After Hours: 10/13/2025, 8:00:00 PM
Fundamental Rating

4

Overall MIRM gets a fundamental rating of 4 out of 10. We evaluated MIRM against 536 industry peers in the Biotechnology industry. MIRM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MIRM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

MIRM had negative earnings in the past year.
MIRM had a positive operating cash flow in the past year.
MIRM had negative earnings in each of the past 5 years.
In the past 5 years MIRM reported 4 times negative operating cash flow.
MIRM Yearly Net Income VS EBIT VS OCF VS FCFMIRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -8.07%, MIRM belongs to the best of the industry, outperforming 85.26% of the companies in the same industry.
MIRM has a Return On Equity of -22.95%. This is amongst the best in the industry. MIRM outperforms 83.02% of its industry peers.
Industry RankSector Rank
ROA -8.07%
ROE -22.95%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
MIRM Yearly ROA, ROE, ROICMIRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

MIRM has a Gross Margin of 79.02%. This is amongst the best in the industry. MIRM outperforms 84.51% of its industry peers.
In the last couple of years the Gross Margin of MIRM has declined.
The Profit Margin and Operating Margin are not available for MIRM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
MIRM Yearly Profit, Operating, Gross MarginsMIRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MIRM has more shares outstanding
The number of shares outstanding for MIRM has been increased compared to 5 years ago.
Compared to 1 year ago, MIRM has an improved debt to assets ratio.
MIRM Yearly Shares OutstandingMIRM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MIRM Yearly Total Debt VS Total AssetsMIRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.22 indicates that MIRM is not in any danger for bankruptcy at the moment.
MIRM's Altman-Z score of 4.22 is fine compared to the rest of the industry. MIRM outperforms 73.69% of its industry peers.
A Debt/Equity ratio of 1.21 is on the high side and indicates that MIRM has dependencies on debt financing.
The Debt to Equity ratio of MIRM (1.21) is worse than 78.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Altman-Z 4.22
ROIC/WACCN/A
WACC9.23%
MIRM Yearly LT Debt VS Equity VS FCFMIRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

MIRM has a Current Ratio of 3.13. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.13, MIRM is doing worse than 62.87% of the companies in the same industry.
A Quick Ratio of 2.97 indicates that MIRM has no problem at all paying its short term obligations.
The Quick ratio of MIRM (2.97) is worse than 61.94% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 2.97
MIRM Yearly Current Assets VS Current LiabilitesMIRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.16% over the past year.
MIRM shows a strong growth in Revenue. In the last year, the Revenue has grown by 62.33%.
Measured over the past years, MIRM shows a very strong growth in Revenue. The Revenue has been growing by 160.12% on average per year.
EPS 1Y (TTM)47.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.92%
Revenue 1Y (TTM)62.33%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%64.09%

3.2 Future

Based on estimates for the next years, MIRM will show a very strong growth in Earnings Per Share. The EPS will grow by 30.85% on average per year.
The Revenue is expected to grow by 24.49% on average over the next years. This is a very strong growth
EPS Next Y60.83%
EPS Next 2Y41.14%
EPS Next 3Y38.8%
EPS Next 5Y30.85%
Revenue Next Year51.23%
Revenue Next 2Y34.62%
Revenue Next 3Y29.32%
Revenue Next 5Y24.49%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MIRM Yearly Revenue VS EstimatesMIRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
MIRM Yearly EPS VS EstimatesMIRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIRM. In the last year negative earnings were reported.
Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRM Price Earnings VS Forward Price EarningsMIRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -1K -2K -3K -4K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRM Per share dataMIRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

MIRM's earnings are expected to grow with 38.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.14%
EPS Next 3Y38.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MIRM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (10/13/2025, 8:00:00 PM)

After market: 72.17 0 (0%)

72.17

-0.54 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners99.48%
Inst Owner Change0.02%
Ins Owners1.88%
Ins Owner Change0.34%
Market Cap3.63B
Analysts85.88
Price Target83.03 (15.05%)
Short Float %17.75%
Short Ratio10.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.33%
Min EPS beat(2)10.69%
Max EPS beat(2)63.96%
EPS beat(4)3
Avg EPS beat(4)2.44%
Min EPS beat(4)-99.42%
Max EPS beat(4)63.96%
EPS beat(8)4
Avg EPS beat(8)-20.49%
EPS beat(12)7
Avg EPS beat(12)-22.94%
EPS beat(16)10
Avg EPS beat(16)-49.5%
Revenue beat(2)2
Avg Revenue beat(2)13.5%
Min Revenue beat(2)11.17%
Max Revenue beat(2)15.82%
Revenue beat(4)4
Avg Revenue beat(4)8.98%
Min Revenue beat(4)0.89%
Max Revenue beat(4)15.82%
Revenue beat(8)7
Avg Revenue beat(8)6.96%
Revenue beat(12)10
Avg Revenue beat(12)7.02%
Revenue beat(16)13
Avg Revenue beat(16)33.62%
PT rev (1m)0.74%
PT rev (3m)15.73%
EPS NQ rev (1m)9.27%
EPS NQ rev (3m)41.74%
EPS NY rev (1m)8.16%
EPS NY rev (3m)36.07%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)15.45%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)12.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.45
P/FCF N/A
P/OCF 403.09
P/B 14.21
P/tB 209.73
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0.18
OCFY0.25%
SpS8.54
BVpS5.08
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.07%
ROE -22.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.02%
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.81%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 2.97
Altman-Z 4.22
F-Score6
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.92%
EPS Next Y60.83%
EPS Next 2Y41.14%
EPS Next 3Y38.8%
EPS Next 5Y30.85%
Revenue 1Y (TTM)62.33%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%64.09%
Revenue Next Year51.23%
Revenue Next 2Y34.62%
Revenue Next 3Y29.32%
Revenue Next 5Y24.49%
EBIT growth 1Y47.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.43%
EBIT Next 3Y45.06%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y109.33%
OCF growth 3YN/A
OCF growth 5YN/A